SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Hauppauge Digital (Nasdaq: HAUP) $3.33, Up $0.96. Today announced a new live TV streamer for the Apple iPhone, iPad and iPod touch. Called “Broadway”, this new stand alone “box” from Hauppauge’s PCTV Systems division allows live TV to be watched on an Apple device in the home through a WiFi connection, or anywhere in the world via an Internet connection.
Broadway can be used in the home, for example, to watch a football game or a news program on your iPad. Your iPad will display a list of Broadway provided TV channels from your cable TV network, and once you have chosen a TV channel, touching the iPad screen with your finger will prompt the live TV program to fill the entire screen.
If you travel and have an Internet connection on your iPhone or iPad, you can watch live TV from your home anywhere in the world. Broadway connects to your home network router and transmits the TV signal through your network router over the Internet to your Apple device.
What They Do: Hauppauge Digital is a leading developer and manufacturer of digital TV and data broadcast receiver products for personal computers.
Lexicon Pharmaceuticals (Nasdaq: LXRX) $1.95, Up $0.44. Today announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).
Results from the study demonstrated that administration of a 300 mg solid oral tablet dose of LX4211, administered as two 150 mg tablets, significantly increased total GLP-1 (p=0.001), active GLP-1 (p=0.032) and PYY (p=0.004), important mediators of glycemic and appetite control as well as other metabolic parameters. Notably, single doses of LX4211 produced rapid and significant improvement in post-prandial glucose (PPG) and fasting plasma glucose (FPG), consistent with results seen in the previous Phase 2 study. Pharmacokinetic and pharmacodynamic data from the study indicated that the solid oral formulation worked as well as or better than the liquid formulation on key parameters of hormonal release, PPG and FPG. Lexicon plans to move the tablet formulation forward into a Phase 2b study in the second quarter of 2011.
What They Do: Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.
Skilled Healthcare Group (NYSE: SKH) $11.09, Up $1.56. Today announced it has updated its 2010 full year non-GAAP earnings estimates and expects consolidated revenue to be approximately $816 million to $819 million, Adjusted EBITDAR to be approximately $138.9 million to $140.7 million and Adjusted EBITDA to be approximately $119.7 million to $121.5 million. The Company expects adjusted earnings per diluted share for 2010 to be between $1.01 and $1.04.
Additionally, the Company issued its initial earnings guidance for 2011 and expects full year consolidated revenue to be between $880 million and $900 million, EBITDAR to be in the range of $156.2 million to $163.5 million, EBITDA to be in the range of $137.2 million to $144.5 million and net income per common share to be between $1.22 and $1.32.
What They Do: Skilled Healthcare Group, Inc., based in Foothill Ranch, California, is a holding company with subsidiary healthcare services companies, which in the aggregate had trailing twelve month revenue of approximately $788 million and approximately 14,600 employees as of September 30, 2010.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.
